Company intelligence / Profile preview

Optibrium

Cambridge, England, United Kingdomoptibrium.com ↗

Ownership: Private
Employees: ~31
Development stage: Commercial

Overview

Optibrium develops and markets advanced in silico and AI-driven software solutions to accelerate small molecule drug discovery, focusing on compound design, optimization, predictive modeling, and data analysis. Their flagship products are widely used by pharmaceutical companies, biotechs, agrochemical firms, flavoring companies, and academic groups to improve R&D efficiency[1][2][3].

Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

Collaborates with leading global pharma companies, biotech firms, agrochemical businesses, flavoring companies as well as academic groupsSpecific partners include Medicines Discovery Catapult via an Innovate UK grant-funded project

Beyond the preview

Go deeper on Optibrium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optibrium.

Explore the full profile